Scientific publications

CD4-modified synthetic peptides containing phenylalanine inhibit HIV-1 infection in vitro

Lasarte JJ, Sarobe P, Golvano J, Prieto I, Civeira MP [SP], Gullón A, Sarin PS, Prieto J, Borrás-Cuesta F.
Departamento de Medicina Interna, Facultad de Medicina, Universidad de Navarra, Pamplona, Spain.

Magazine: Journal of Acquired Inmune Deficiency Syndromes

Date: Feb 1, 1994

Internal Medicine [SP]

Phenylalanine-containing peptides from CD4 were synthesized based on chemical similarity with active CD4(81-92)-benzylated peptides. The synthetic peptide FYIFFVEDQKEEDD blocked the binding of gp120 to CD4 and inhibited 50% human immunodeficiency virus (HIV)-induced syncytia formation at a concentration (IC50) of approximately 40-50 microM and HIV p17 expression with an IC50 of approximately 67 microM.

The peptide is not toxic to cells in vitro. Moreover, acute toxicity studies carried out in Swiss mice showed the peptide to be nontoxic at a dose of 2,000 mg/kg. This phenylalanine-substituted CD4 peptide may prove to be useful in the treatment of AIDS.

CITATION  J Acquir Immune Defic Syndr. 1994 Feb;7(2):129-34

you mayBE INTERESTED

WHAT TECHNOLOGY
DO WE USE?

The Clínica is the greater private hospital with technological equipment of Spain, all in a single center.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra

OUR
PROFESSIONALS

The professionals of the Clínica perform continuous research and training, always to the benefit of the patient.

Imagen profesionales de la Clínica Universidad de Navarra

WHY CHOOSE
THE CLINICA?

Learn why we are different from other healthcare centers. Quality, speed, comfort and results.

Imagen del edificio de la Clínica Universidad de Navarra